The estrogen receptor CpG island is methylated in most hematopoietic neoplasms

Jean Pierre J. Issa, Barbara A. Zehnbauer, Curt I. Civin, Michael I. Collector, Saul J. Sharkis, Nancy E. Davidson, Scott H. Kaufmann, Stephen B. Baylin

Research output: Contribution to journalArticlepeer-review

141 Scopus citations


Estrogen appears to be a negative regulator of normal hematopoiesis. Chromosome 6q, which contains the estrogen receptor (ER) gene, is frequently altered in human hematopoietic neoplasms. The ER gene, which has growth and metastasis suppressor activity in many different cell types, is inactivated by promoter methylation in some ER-negative breast tumors and 100% of colorectal tumors. We now report that the promoter region of the ER gene is aberrantly methylated in 86% of human hematopoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myelogenous leukemia, 3 of 6 chronic phase chronic myelogenous leukemia, 9 of 9 blast crisis chronic myelogenous leukemia and 5 of 8 lymphomas. This methylation event was also present in all nine leukemia cell lines examined, where it was associated with very low or absent ER expression. In addition, rat and mouse leukemia cell lines also exhibited this change, indicating that ER CpG island methylation in leukemias is conserved among species. Our results suggest that ER CpG island methylation could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for monitoring the clinical status of these diseases.

Original languageEnglish (US)
Pages (from-to)973-977
Number of pages5
JournalCancer research
Issue number5
StatePublished - Mar 1 1996

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The estrogen receptor CpG island is methylated in most hematopoietic neoplasms'. Together they form a unique fingerprint.

Cite this